Renalys Pharma announces completion of patient enrollment in registrational Phase III clinical trial of sparsentan for IgA nephropathy in Japan January 29, 2025
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy September 6, 2024
Renalys Pharma announces first patient dosed in registrational Phase III clinical trial of sparsentan for IgA nephropathy in Japan July 18, 2024
Renalys Pharma Closes ¥6.0Bn Series A Financing to Advance Kidney Disease Treatments Across Asia July 17, 2024
The Japan Kidney Association and Renalys Pharma Form Collaborative Agreement to overcome kidney disease May 7, 2024
Renalys Pharma Submits an IND Application for a Phase III Clinical Trial of sparsentan for IgA Nephropathy in Japan April 7, 2024
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy February 27, 2024
